Deals this week: Ascend Therapeutics US, Tyme Technologies, Axsome Therapeutics


Ascend Therapeutics US will be the exclusive seller and marketer of Aevum Life Science's Protiva Pregnancy and Protiva New Mom / Recover products across the US, under an agreement signed between the two companies.

The products are useful for improving quality of life for women during pregnancy and post-delivery.

Canadian biopharmaceutical company Aeterna Zentaris intends to issue shares of its common stock in order to raise $50m in gross proceeds.

The proceeds are intended to be used for general corporate purposes.

Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors.

The proceeds are intended to be used for initiating Phase II clinical trial in pancreatic cancer and build out its operating structure.

"Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors."

Based in the US, the company is focused on cancer therapeutics.

US-based biopharmaceutical company Axsome Therapeutics intends to offer shares of its common stock to public through underwriters, who will have a 30-day option to purchase up to an additional 15% of the shares.

The proceeds are intended to fund the company’s ongoing clinical trials, and for working capital and general corporate purposes. The remaining funds will be invested in short-term, investment-grade, interest-bearing instruments and US government securities.

La Jolla Pharmaceutical Company, also a biopharmaceutical company based in the US, intends to raise $100m through a similar offering.

The proceeds are intended to be used for general corporate purposes.